Dubsky, Peter http://orcid.org/0000-0002-9566-0209
Jackisch, Christian http://orcid.org/0000-0001-8537-3743
Im, Seock-Ah
Hunt, Kelly K. http://orcid.org/0000-0001-9156-8723
Li, Chien-Feng
Unger, Sheila
Paluch-Shimon, Shani
Funding for this research was provided by:
AstraZeneca
Merck
Merck
Merck
Merck
Merck
Merck
Merck
Article History
Received: 26 February 2024
Accepted: 19 August 2024
First Online: 5 September 2024
Competing interests
: C.J. has received consultancy fees from AstraZeneca, Daiichi Sankyo, Eli Lilly & Co., Novartis, and Roche; received support for travel or to attend meetings from Daiichi Sankyo, Pierre Fabre, and Roche; and has an unpaid role on the AGO Task Force for treatment recommendations on diagnosis and therapy in breast cancer. K.K.H. has received research funding to her institution from Cairn Surgical, Eli Lilly & Co., and Lumicell; is an Editor for <i>Current Breast Cancer Reports</i> (Springer); has received consultancy fees from Armada Health and honoraria for lectures and educational events from AstraZeneca. P.D. has received grants to his institution from Bristol Myers Squibb, MSD, and Roche to support patient activities; consultancy fees to his institution from AstraZeneca, MSD, and Roche; payments for speaking engagements or educational activities to his institution from AstraZeneca; and support to his institution for attending meetings or travel from Roche. S-A.I. has received grants from AstraZeneca, Boryung, Eisai, Daewoong Pharmaceutical, Daiichi Sankyo, Pfizer, and Roche; and consultancy fees from AstraZeneca, Bertis, Daiichi Sankyo, Eisai, Eli Lilly & Co, GSK, Hanmi, Idience, MSD, Novartis, Pfizer, and Roche. S.P-S. has received an independent research grant from Pfizer; consultancy fees to their institution from AstraZeneca, Daiichi Sankyo, Eli Lilly & Co., Gilead, Medison, MSD, Novartis, Pfizer, Roche, and Sharing Progress in Cancer Care; support to their institution for attending meetings and/or travel from Gilead, Pfizer, and Roche; and is the Subject Editor for breast cancer and on the clinical practice guideline committee of the European Society for Medical Oncology (ESMO). S.U. has received honoraria to her institution for speaking engagements or educational events. C-F.L. has no competing interests to disclose.